- Home
- BIIB vs CBOE Comparison
BIIB vs CBOE Comparison
Compare BIIB & CBOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CBOE
- Stock Information
- Founded
- BIIB 1978
- CBOE 1973
- Country
- BIIB United States
- CBOE United States
- Employees
- BIIB N/A
- CBOE 1647
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CBOE Investment Bankers/Brokers/Service
- Sector
- BIIB Health Care
- CBOE Finance
- Exchange
- BIIB Nasdaq
- CBOE Nasdaq
- Market Cap
- BIIB 25.1B
- CBOE 22.7B
- IPO Year
- BIIB 1991
- CBOE 2010
- Fundamental
- Price
- BIIB $164.78
- CBOE $214.17
- Analyst Decision
- BIIB Buy
- CBOE Buy
- Analyst Count
- BIIB 25
- CBOE 12
- Target Price
- BIIB $260.48
- CBOE $209.42
- AVG Volume (30 Days)
- BIIB 1.7M
- CBOE 1.2M
- Earning Date
- BIIB 10-30-2024
- CBOE 11-01-2024
- Dividend Yield
- BIIB N/A
- CBOE 1.17%
- EPS Growth
- BIIB 10.05
- CBOE 10.63
- EPS
- BIIB 11.06
- CBOE 7.34
- Revenue
- BIIB $9,607,500,000.00
- CBOE $3,955,600,000.00
- Revenue This Year
- BIIB N/A
- CBOE N/A
- Revenue Next Year
- BIIB N/A
- CBOE $4.85
- P/E Ratio
- BIIB $14.52
- CBOE $29.40
- Revenue Growth
- BIIB N/A
- CBOE 3.84
- 52 Week Low
- BIIB $153.62
- CBOE $166.13
- 52 Week High
- BIIB $268.30
- CBOE $221.66
- Technical
- Relative Strength Index (RSI)
- BIIB 35.71
- CBOE 58.59
- Support Level
- BIIB $158.44
- CBOE $210.23
- Resistance Level
- BIIB $161.67
- CBOE $221.66
- Average True Range (ATR)
- BIIB 3.88
- CBOE 4.67
- MACD
- BIIB 0.75
- CBOE 1.48
- Stochastic Oscillator
- BIIB 34.35
- CBOE 71.76
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CBOE Cboe Global Markets Inc.
Cboe global Markets, Inc is a provider of market infrastructure and tradable products, delivers cutting-edge trading, clearing and investment solutions to market participants around the world. The Company is committed to operating a trusted, inclusive global marketplace, and to providing leading products, technology and data solutions that enable participants to define a sustainable financial future. Cboe provides trading solutions and products in multiple asset classes, including equities, derivatives, FX, and digital assets, across North America, Europe, and Asia Pacific.